Abstract
The T790M mutation in EGFR accounts for approximately half of all lung cancer cases with acquired resistance to the current clinical EGFR tyrosine kinase inhibitors. In tyrosine kinase inhibitor-resistant lung tumors, rociletinib and AZD9291 are highly active when T790M is present and modestly active when T790M is absent.
Copyright © 2015 Elsevier Inc. All rights reserved.
MeSH terms
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / enzymology
-
Carcinoma, Non-Small-Cell Lung / genetics
-
Carcinoma, Non-Small-Cell Lung / pathology
-
ErbB Receptors / antagonists & inhibitors*
-
ErbB Receptors / genetics
-
ErbB Receptors / metabolism
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / enzymology
-
Lung Neoplasms / genetics
-
Lung Neoplasms / pathology
-
Mutation
-
Protein Kinase Inhibitors / pharmacology*
Substances
-
Protein Kinase Inhibitors
-
EGFR protein, human
-
ErbB Receptors